Immuneering (IMRX) Stock Forecast, Price Target & Predictions

IMRX Stock Forecast

Immuneering stock forecast is as follows: an average price target of $17.50 (represents a 729.38% upside from IMRX’s last price of $2.11) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

IMRX Price Target

The average price target for Immuneering (IMRX) is $17.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $41.00 to $3.00. This represents a potential 729.38% upside from IMRX's last price of $2.11.

IMRX Analyst Ratings

Buy

According to 3 Wall Street analysts, Immuneering's rating consensus is 'Buy'. The analyst rating breakdown for IMRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immuneering Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 02, 2024	Graig Suvannavejh	Mizuho Securities	$8.00	$2.75	190.91%	279.15%
Mar 15, 2024	Michael Yee	Jefferies	$3.00	$1.91	57.07%	42.18%
Sep 30, 2022	Swapnil Malekar	Piper Sandler	$41.00	$15.50	164.52%	1843.13%
Jul 09, 2022	Geulah Livshits	Loop Capital Markets	$18.00	$7.28	147.25%	753.08%

Row per page

Go to

The latest Immuneering stock forecast, released on Apr 02, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $8.00, which represents a 190.91% increase from the stock price at the time of the forecast ($2.75), and a 279.15% increase from IMRX last price ($2.11).

Immuneering Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$5.50
Last Closing Price	$2.11	$2.11	$2.11
Upside/Downside	-100.00%	-100.00%	160.66%

In the current month, the average price target of Immuneering stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immuneering's last price of $2.11. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Apr 19, 2023	Mizuho Securities	-	Buy	Upgrade
Jul 25, 2022	Piper Sandler	Overweight	Overweight	Hold
Jul 09, 2022	Chardan Capital	-	Buy	Initialise

Row per page

Go to

Immuneering's last stock rating was published by Mizuho Securities on Apr 19, 2023. The company Upgrade its IMRX rating from "null" to "Buy".

Immuneering Financial Forecast

Immuneering Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	-	-	-	-	$456.00	$38.38K	$94.42K	$183.70K	$2.08B	$482.13K	$660.04K
Avg Forecast	-	-	-	-	-	-	-	$8.33K	$60.00K	$153.33K	$196.80K	$182.00K	$535.50K	$700.00K	$725.00K
High Forecast	-	-	-	-	-	-	-	$8.33K	$60.00K	$153.33K	$196.80K	$182.00K	$535.50K	$700.00K	$725.00K
Low Forecast	-	-	-	-	-	-	-	$8.33K	$60.00K	$153.33K	$196.80K	$182.00K	$535.50K	$700.00K	$725.00K
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	0.01%	0.25%	0.48%	1.01%	3880.62%	0.69%	0.91%

Immuneering's average Quarter revenue forecast for Mar 23 based on 1 analysts is $8.33K, with a low forecast of $8.33K, and a high forecast of $8.33K. IMRX's average Quarter revenue forecast represents a 1727.41% increase compared to the company's last Quarter revenue of $456.00 (Dec 22).

Immuneering EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	$-14.49M	$-13.98M	$-12.98M	$-11.44M	$-12.73M	$-14.68M	$-8.50M	$-7.95M
Avg Forecast	-	-	-	-	-	-	-	$-5.00K	$-36.00K	$-92.00K	$-118.08K	$-11.45M	$-321.30K	$-10.45M	$-435.00K
High Forecast	-	-	-	-	-	-	-	$-5.00K	$-36.00K	$-92.00K	$-118.08K	$-9.16M	$-321.30K	$-8.36M	$-435.00K
Low Forecast	-	-	-	-	-	-	-	$-5.00K	$-36.00K	$-92.00K	$-118.08K	$-13.74M	$-321.30K	$-12.54M	$-435.00K
Surprise %	-	-	-	-	-	-	-	2898.50%	388.27%	141.13%	96.91%	1.11%	45.69%	0.81%	18.27%

undefined analysts predict IMRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immuneering's previous annual EBITDA (undefined) of $NaN.

Immuneering Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	$1.06B	$-12.51M	$-12.50M	$-11.41M	$-12.87M	$-14.37M	$-8.53M	$-7.99M
Avg Forecast	$-8.95M	$-8.95M	$-8.95M	$-8.95M	$-13.68M	$-16.47M	$-15.42M	$-16.15M	$-16.75M	$-14.23M	$-15.21M	$-11.75M	$-11.45M	$-10.49M	$-49.08M
High Forecast	$-8.95M	$-8.95M	$-8.95M	$-7.46M	$-8.55M	$-16.47M	$-15.42M	$-16.15M	$-16.75M	$-14.23M	$-15.21M	$-9.40M	$-11.45M	$-8.39M	$-49.08M
Low Forecast	$-8.95M	$-8.95M	$-8.95M	$-10.20M	$-17.67M	$-16.47M	$-15.42M	$-16.15M	$-16.75M	$-14.23M	$-15.21M	$-14.10M	$-11.45M	$-12.59M	$-49.08M
Surprise %	-	-	-	-	-	-	-	-65.74%	0.75%	0.88%	0.75%	1.10%	1.26%	0.81%	0.16%

Immuneering's average Quarter net income forecast for Jun 24 is $-15.42M, with a range of $-15.42M to $-15.42M. IMRX's average Quarter net income forecast represents a -101.45% decrease compared to the company's last Quarter net income of $1.06B (Mar 23).

Immuneering SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	$4.46M	$4.11M	$3.84M	$3.70M	$3.95M	$3.79M	$2.60M	$1.34M
Avg Forecast	-	-	-	-	-	-	-	$94.95K	$683.67K	$1.75M	$2.24M	$2.07M	$6.10M	$7.98M	$8.26M
High Forecast	-	-	-	-	-	-	-	$94.95K	$683.67K	$1.75M	$2.24M	$2.07M	$6.10M	$7.98M	$8.26M
Low Forecast	-	-	-	-	-	-	-	$94.95K	$683.67K	$1.75M	$2.24M	$2.07M	$6.10M	$7.98M	$8.26M
Surprise %	-	-	-	-	-	-	-	46.98%	6.01%	2.20%	1.65%	1.91%	0.62%	0.33%	0.16%

Immuneering's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to IMRX last annual SG&A of $4.46M (Mar 23).

Immuneering EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	$40.16	$-0.47	$-0.47	$-0.43	$-0.49	$-0.55	$-0.47	$-0.33
Avg Forecast	$-0.30	$-0.30	$-0.30	$-0.30	$-0.46	$-0.55	$-0.52	$-0.54	$-0.56	$-0.48	$-0.51	$-0.44	$-0.39	$-0.56	$-1.66
High Forecast	$-0.30	$-0.30	$-0.30	$-0.25	$-0.29	$-0.55	$-0.52	$-0.54	$-0.56	$-0.48	$-0.51	$-0.44	$-0.39	$-0.56	$-1.66
Low Forecast	$-0.30	$-0.30	$-0.30	$-0.34	$-0.59	$-0.55	$-0.52	$-0.54	$-0.56	$-0.48	$-0.51	$-0.44	$-0.39	$-0.56	$-1.66
Surprise %	-	-	-	-	-	-	-	-74.20%	0.84%	0.98%	0.84%	1.12%	1.42%	0.84%	0.20%

According to 0 Wall Street analysts, Immuneering's projected average Quarter EPS for Jun 24 is $-0.52, with a low estimate of $-0.52 and a high estimate of $-0.52. This represents a -101.29% decrease compared to IMRX previous annual EPS of $40.16 (Mar 23).

Immuneering Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IVA	Inventiva	$2.66	$36.00	1253.38%	Buy
PMVP	PMV Pharmaceuticals	$1.61	$18.00	1018.01%	Buy
IMRX	Immuneering	$2.11	$17.50	729.38%	Buy
GOSS	Gossamer Bio	$0.66	$3.75	468.18%	Buy
CMPX	Compass Therapeutics	$1.38	$5.00	262.32%	Buy
LRMR	Larimar Therapeutics	$6.13	$20.33	231.65%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
CGEM	Cullinan Oncology	$12.22	$31.50	157.77%	Buy
CELC	Celcuity	$12.73	$31.50	147.45%	Buy
REPL	Replimune Group	$11.05	$24.20	119.00%	Buy
KRON	Kronos Bio	$0.87	$1.63	87.36%	Buy
NAMS	NewAmsterdam Pharma Company	$20.12	$36.50	81.41%	Buy
ELVN	Enliven Therapeutics	$25.41	$39.50	55.45%	Buy
CNTA	Centessa Pharmaceuticals	$18.19	$23.25	27.82%	Buy
IKNA	Ikena Oncology	$1.73	$1.33	-23.12%	Buy

IMRX Forecast FAQ

Is Immuneering a good buy?

Yes, according to 3 Wall Street analysts, Immuneering (IMRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of IMRX's total ratings.

What is IMRX's price target?

Immuneering (IMRX) average price target is $17.5 with a range of $3 to $41, implying a 729.38% from its last price of $2.11. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Immuneering stock go up soon?

According to Wall Street analysts' prediction for IMRX stock, the company can go up by 729.38% (from the last price of $2.11 to the average price target of $17.5), up by 1843.13% based on the highest stock price target, and up by 42.18% based on the lowest stock price target.

Can Immuneering stock reach $3?

IMRX's average twelve months analyst stock price target of $17.5 supports the claim that Immuneering can reach $3 in the near future.

What are Immuneering's analysts' financial forecasts?

Immuneering's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-45.566M (high $-40.437M, low $-49.555M), average SG&A $0 (high $0, low $0), and average EPS is $-1.53 (high $-1.358, low $-1.664). IMRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-35.81M (high $-34.318M, low $-37.054M), average SG&A $0 (high $0, low $0), and average EPS is $-1.2 (high $-1.15, low $-1.242).

Did the IMRX's actual financial results beat the analysts' financial forecasts?

Based on Immuneering's last annual report (Dec 2022), the company's revenue was $316.95K, which missed the average analysts forecast of $592.13K by -46.47%. Apple's EBITDA was $-51.715M, beating the average prediction of $-11.693M by 342.29%. The company's net income was $-49.282M, missing the average estimation of $-57.946M by -14.95%. Apple's SG&A was $15.61M, beating the average forecast of $6.75M by 131.31%. Lastly, the company's EPS was $-1.87, missing the average prediction of $-1.993 by -6.15%. In terms of the last quarterly report (Dec 2022), Immuneering's revenue was $456, missing the average analysts' forecast of $60K by -99.24%. The company's EBITDA was $-13.978M, beating the average prediction of $-36K by 38726.92%. Immuneering's net income was $-12.506M, missing the average estimation of $-16.754M by -25.36%. The company's SG&A was $4.11M, beating the average forecast of $683.67K by 500.63%. Lastly, the company's EPS was $-0.47, missing the average prediction of $-0.561 by -16.29%